0JXZ.LSE Galapagos N.V.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is 0JXZ.LSE undervalued?
Graham numberThe Graham number of Galapagos N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galapagos N.V. fundamental analysis
No fundamental analysis for Galapagos N.V. yet.
Galapagos N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galapagos N.V.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product ca…
Full company profileGalapagos N.V. financial statements
Galapagos N.V. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 152M | 156M | 318M | 886M | 530M | - | - |
| Operating Income | -11.5M | -89.8M | -44.8M | 369M | -179M | - | - |
| Net Income | 54.0M | -116M | -29.3M | 150M | -305M | - | - |
| Balance Sheet | |||||||
| Total Assets | 1.08B | 1.29B | 1.44B | 6.07B | 5.72B | - | - |
| Total Liabilities | 325M | 274M | 225M | 3.19B | 3.05B | - | - |
| Shareholders' Equity | 759M | 1.01B | 1.21B | 2.88B | 2.67B | - | - |
| Cash & Short-term Investments | 973M | 1.15B | 1.29B | 5.78B | 5.16B | - | - |
| Total Debt | 9.00K | - | - | 19.6M | 23.0M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 239M | -147M | -142M | 3.21B | -427M | -504M | -501M |
| Capital Expenditure | 4.79M | 7.44M | 10.4M | 22.4M | 42.5M | 54.2M | 27.4M |
| Ratios | |||||||
| ROE | 7.1% | -11.4% | -2.4% | 5.2% | -11.4% | - | - |
| ROA | 5.0% | -9.0% | -2.0% | 2.5% | -5.3% | - | - |
| Net Profit Margin | 35.6% | -74.2% | -9.2% | 16.9% | -57.6% | - | - |
| Debt to Equity | 0.00x | - | - | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Galapagos N.V. dividends
Galapagos N.V. has not paid dividends in the last 9 fiscal years.
Who owns Galapagos N.V.
- Insiders 25.36%
- Institutions 43.60%
- Public & others 31.04%
- Free float 23.1M
Galapagos N.V. company profile
- Company name
- Galapagos N.V.
- Ticker
- 0JXZ.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 196
- Fiscal year end
- December
- Address
- SchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800
- Phone
- 32 1 534 29 00
- Website
- lakefrontbio.com
About Galapagos N.V.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos N.V. management
10- Mr. Henry O. GosebruchCEO & Executive Director · born 1973
- Mr. Aaron L. CoxChief Financial Officer · born 1984
- Ms. Christina Carlson J.D.Chief Operating Officer
- Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
- Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
- Marieke VermeerschHead of Corporate Communication
- Ms. Tania PhilippChief People Officer · born 1972
- Ms. Ellen Van Der AarHead of Development
- Dr. Jeevan ShettyHead of Clinical Development Oncology
- Ruiz AstigarragaHead of Manufacturing Cell Therapy